Point72 Asia Singapore Pte. Ltd. Makes New $28,000 Investment in Ascendis Pharma A/S (NASDAQ:ASND)

Point72 Asia Singapore Pte. Ltd. purchased a new position in shares of Ascendis Pharma A/S (NASDAQ:ASND) in the 4th quarter, Holdings Channel reports. The firm purchased 202 shares of the biotechnology company’s stock, valued at approximately $28,000.

Several other hedge funds also recently bought and sold shares of ASND. T. Rowe Price Investment Management Inc. increased its position in Ascendis Pharma A/S by 54.4% during the fourth quarter. T. Rowe Price Investment Management Inc. now owns 2,725,546 shares of the biotechnology company’s stock worth $375,226,000 after buying an additional 960,504 shares in the last quarter. Capital International Investors increased its position in Ascendis Pharma A/S by 35.7% during the fourth quarter. Capital International Investors now owns 2,863,249 shares of the biotechnology company’s stock worth $394,183,000 after buying an additional 753,859 shares in the last quarter. RA Capital Management L.P. increased its position in Ascendis Pharma A/S by 4.1% during the fourth quarter. RA Capital Management L.P. now owns 10,112,744 shares of the biotechnology company’s stock worth $1,392,221,000 after buying an additional 402,316 shares in the last quarter. Janus Henderson Group PLC increased its position in Ascendis Pharma A/S by 4.6% during the fourth quarter. Janus Henderson Group PLC now owns 4,380,382 shares of the biotechnology company’s stock worth $602,910,000 after buying an additional 193,688 shares in the last quarter. Finally, Price T Rowe Associates Inc. MD increased its position in Ascendis Pharma A/S by 7.6% during the fourth quarter. Price T Rowe Associates Inc. MD now owns 2,283,207 shares of the biotechnology company’s stock worth $314,330,000 after buying an additional 162,079 shares in the last quarter.

Analyst Upgrades and Downgrades

A number of brokerages have recently commented on ASND. JPMorgan Chase & Co. lifted their price objective on Ascendis Pharma A/S from $200.00 to $245.00 and gave the company an “overweight” rating in a research report on Friday, May 2nd. Evercore ISI lifted their price objective on Ascendis Pharma A/S from $260.00 to $280.00 and gave the company an “outperform” rating in a research report on Friday, May 2nd. Wedbush lifted their price objective on Ascendis Pharma A/S from $181.00 to $212.00 and gave the company an “outperform” rating in a research report on Friday, May 2nd. The Goldman Sachs Group lifted their price objective on Ascendis Pharma A/S from $200.00 to $225.00 and gave the company a “buy” rating in a research report on Thursday, February 13th. Finally, Cantor Fitzgerald reiterated an “overweight” rating and issued a $200.00 target price on shares of Ascendis Pharma A/S in a report on Monday, May 12th. One equities research analyst has rated the stock with a hold rating and fifteen have assigned a buy rating to the stock. According to MarketBeat, the company presently has a consensus rating of “Moderate Buy” and an average price target of $216.07.

Ascendis Pharma A/S Price Performance

Shares of ASND opened at $160.33 on Tuesday. The stock’s 50-day moving average is $157.35 and its two-hundred day moving average is $142.88. The stock has a market cap of $9.78 billion, a PE ratio of -22.58 and a beta of 0.41. Ascendis Pharma A/S has a 12 month low of $111.09 and a 12 month high of $183.00.

Ascendis Pharma A/S (NASDAQ:ASND) last issued its quarterly earnings data on Thursday, May 1st. The biotechnology company reported ($1.66) EPS for the quarter, missing analysts’ consensus estimates of ($1.56) by ($0.10). The business had revenue of $123.97 million during the quarter, compared to the consensus estimate of $98.56 million. On average, research analysts anticipate that Ascendis Pharma A/S will post -4.34 earnings per share for the current year.

Ascendis Pharma A/S Profile

Ascendis Pharma A/S, a biopharmaceutical company, focuses on developing therapies for unmet medical needs. It offers SKYTROFA for treating patients with growth hormone deficiency (GHD). The company is also developing a pipeline of three independent endocrinology rare disease product candidates in clinical development, as well as focuses on advancing oncology therapeutic candidates.